share_log

Thermo Fisher Scientific | 8-K: Thermo Fisher Scientific Reports Third Quarter 2024 Results

Thermo Fisher Scientific | 8-K: Thermo Fisher Scientific Reports Third Quarter 2024 Results

赛默飞世尔 | 8-K：赛默飞世尔科学公布2024年第三季度业绩
美股SEC公告 ·  2024/10/23 03:06

Moomoo AI 已提取核心信息

Thermo Fisher Scientific reported flat revenue of $10.60 billion in Q3 2024, with GAAP EPS at $4.25 and adjusted EPS at $5.28. The company's GAAP operating margin was 17.3%, while adjusted operating margin reached 22.3%. Sequential improvement was observed in growth metrics compared to Q2.The company continued to advance its growth strategy through product innovation, launching the Thermo Scientific Iliad scanning transmission electron microscope for advanced materials research, and new life sciences solutions including the Applied Biosystems MagMAX Sequential DNA/RNA kit and Invitrogen Vivofectamine Delivery Solutions. Strategic partnerships were expanded with the National Cancer Institute and facility expansions in Cincinnati, Ohio, and Bend, Oregon.Looking ahead, Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07, while maintaining revenue guidance of $42.4-$43.3 billion. The company's strong commercial performance and operational execution through its PPI Business System position it well to deliver on 2024 objectives.
Thermo Fisher Scientific reported flat revenue of $10.60 billion in Q3 2024, with GAAP EPS at $4.25 and adjusted EPS at $5.28. The company's GAAP operating margin was 17.3%, while adjusted operating margin reached 22.3%. Sequential improvement was observed in growth metrics compared to Q2.The company continued to advance its growth strategy through product innovation, launching the Thermo Scientific Iliad scanning transmission electron microscope for advanced materials research, and new life sciences solutions including the Applied Biosystems MagMAX Sequential DNA/RNA kit and Invitrogen Vivofectamine Delivery Solutions. Strategic partnerships were expanded with the National Cancer Institute and facility expansions in Cincinnati, Ohio, and Bend, Oregon.Looking ahead, Thermo Fisher raised its full-year adjusted EPS guidance to $21.35-$22.07, while maintaining revenue guidance of $42.4-$43.3 billion. The company's strong commercial performance and operational execution through its PPI Business System position it well to deliver on 2024 objectives.
赛默飞世尔报告称，2024年第三季度营业收入持平为106亿美元，GAAP 每股收益为4.25美元，调整后的每股收益为5.28美元。该公司的GAAP营业利润率为17.3%，而调整后的营业利润率达到了22.3%。与第二季度相比，增长指标显示出逐步改善。该公司通过产品创新继续推进其增长策略，推出了赛默飞世尔Iliad扫描型变速器电子显微镜，用于先进材料研究，以及新的生命科学解决方案，包括应用生物系统MagMAX顺序DNA/RNA试剂盒和Invitrogen Vivofectamine传递解决方案。与国家癌症研究所的战略合作关系得到扩大，同时在俄亥俄州辛辛那提和俄勒冈州本德的设施扩展也正在进行。展望未来，赛默飞世尔将全年的调整后每股收益指导提高至21.35-22.07美元，同时保持营业收入指导在424-433亿的区间。该公司强劲的商业表现和通过其PPI业务系统的运营执行，使其在2024年的目标上具有良好交付能力。
赛默飞世尔报告称，2024年第三季度营业收入持平为106亿美元，GAAP 每股收益为4.25美元，调整后的每股收益为5.28美元。该公司的GAAP营业利润率为17.3%，而调整后的营业利润率达到了22.3%。与第二季度相比，增长指标显示出逐步改善。该公司通过产品创新继续推进其增长策略，推出了赛默飞世尔Iliad扫描型变速器电子显微镜，用于先进材料研究，以及新的生命科学解决方案，包括应用生物系统MagMAX顺序DNA/RNA试剂盒和Invitrogen Vivofectamine传递解决方案。与国家癌症研究所的战略合作关系得到扩大，同时在俄亥俄州辛辛那提和俄勒冈州本德的设施扩展也正在进行。展望未来，赛默飞世尔将全年的调整后每股收益指导提高至21.35-22.07美元，同时保持营业收入指导在424-433亿的区间。该公司强劲的商业表现和通过其PPI业务系统的运营执行，使其在2024年的目标上具有良好交付能力。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    OncoCyte
    OCX
    -- 2.8000
    Opko健康
    OPK
    -- 1.740
    CareDx
    CDNA
    -- 22.150
    Star Equity
    STRR
    -- 2.2750
    iSpecimen
    ISPC
    -- 1.660
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股集体大涨！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 $阿里巴巴 (BABA.US)$ 、 $京东 (JD.US)$ 、 $富途控股 (FUTU.US)$ 等中概股价格飙升，市场情绪火热。 🎙️讨论： Deepseek 展开
    中国股票的疯狂反弹暂停？华尔街仍在大举押注热门股票